DK0485563T3 - Polyether-substituted anti-tumor agents - Google Patents
Polyether-substituted anti-tumor agentsInfo
- Publication number
- DK0485563T3 DK0485563T3 DK91910296.2T DK91910296T DK0485563T3 DK 0485563 T3 DK0485563 T3 DK 0485563T3 DK 91910296 T DK91910296 T DK 91910296T DK 0485563 T3 DK0485563 T3 DK 0485563T3
- Authority
- DK
- Denmark
- Prior art keywords
- substituted
- polyether
- amino group
- tumor agents
- polyethylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
- Polyethers (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Substances for treating or diagnosing tumours, with preferred concentration in the tumor, are characterized in that they have at least two phenolic hydroxyl and/or amino groups, at least one aliphatic amino group, or at least one phenolic hydroxyl and/or amino group and at least one aliphatic amino group, and these groups are substituted with polyethylene glycol chains, whose degree of polymerization n is 5 to 250 and whose terminal hydroxyl group is substituted by C1?-C12? alkyl ester or ether, each substance being substituted by at least two such polyethylene glycol chains.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4017439A DE4017439C2 (en) | 1990-05-30 | 1990-05-30 | Polyether-substituted tumor agents |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0485563T3 true DK0485563T3 (en) | 1995-03-20 |
Family
ID=6407498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK91910296.2T DK0485563T3 (en) | 1990-05-30 | 1991-05-29 | Polyether-substituted anti-tumor agents |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0485563B1 (en) |
JP (1) | JP2640293B2 (en) |
AT (1) | ATE115864T1 (en) |
DE (2) | DE59103985D1 (en) |
DK (1) | DK0485563T3 (en) |
ES (1) | ES2068587T3 (en) |
WO (1) | WO1991018630A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5871710A (en) * | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
EP0665729B1 (en) * | 1992-09-04 | 2003-05-07 | The General Hospital Corporation | Biocompatible polymers containing diagnostic or therapeutic moieties |
US5817292A (en) * | 1992-10-14 | 1998-10-06 | Nycomed Imaging As | MR imaging compositions and methods |
EP0664819B1 (en) * | 1992-10-14 | 1997-08-06 | Nycomed Imaging As | Chelating polymers |
AU5355094A (en) * | 1992-10-14 | 1994-05-09 | Sterling Winthrop Inc. | Therapeutic and diagnostic imaging compositions and methods |
US5605672A (en) * | 1993-06-09 | 1997-02-25 | The General Hospital Corporation | Blood pool imaging composition and method of its use |
GB9408746D0 (en) * | 1994-05-03 | 1994-06-22 | Scotia Holdings Plc | Tumour locallising photosensitising compounds |
US7255851B2 (en) | 1994-07-01 | 2007-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive localization of a light-emitting conjugate in a mammal |
TW319763B (en) * | 1995-02-01 | 1997-11-11 | Epix Medical Inc | |
DE19514087A1 (en) * | 1995-04-13 | 1996-10-17 | Deutsches Krebsforsch | Conjugate of an active ingredient, a polyether and possibly a native protein that is not considered foreign to the body |
DE19706490C1 (en) | 1997-02-19 | 1998-09-17 | Deutsches Krebsforsch | Process for the preparation of acid amides and for the metallization of compounds and use of the compounds produced by the processes |
ATE257014T1 (en) * | 1997-04-29 | 2004-01-15 | Amersham Health As | LIGHT IMAGING CONTRAST AGENTS |
ES2237146T3 (en) | 1998-08-28 | 2005-07-16 | Destiny Pharma Limited | DERIVATIVES OF PORFIRINA, ITS USE IN PHOTODYNAMIC THERAPY AND MEDICAL DEVICES CONTAINING THEM. |
GB0005855D0 (en) * | 2000-03-10 | 2000-05-03 | Scotia Holdings Plc | Compounds for pdt |
ITPD20030174A1 (en) * | 2003-07-31 | 2003-10-29 | Univ Padova | POLYMERIC CONJUGATES FOR DIAGNOSTICS AND THERAPY |
IL168184A (en) * | 2005-04-21 | 2011-11-30 | Univ Ariel Res & Dev Co Ltd | Use of a ligand-photosensitizer conjugate in combination with a chemiluminescent agent in the manufacture of a medicament for photodynamic therapy |
US8853247B2 (en) | 2007-11-02 | 2014-10-07 | Nektar Therapeutics | Oligomer-nitroimidazole anti-infective conjugates |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4824659A (en) * | 1985-06-07 | 1989-04-25 | Immunomedics, Inc. | Antibody conjugates |
DE3546150A1 (en) * | 1985-06-24 | 1987-01-22 | Hoechst Ag | MEMBRANE ANCHOR ACTIVE CONJUGATE, ITS PRODUCTION AND USE |
US4830847A (en) * | 1985-06-28 | 1989-05-16 | The Procter & Gamble Company | Diphosphonate-derivatized macromolecules |
IN165717B (en) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
CA1308377C (en) * | 1987-08-21 | 1992-10-06 | Henry Berger, Jr. | Complex of polyethyleneglycol and tissue plasminogen activator |
JPH0751592B2 (en) * | 1987-12-28 | 1995-06-05 | 帝人株式会社 | Cyclotriphosphazene derivative |
DE3809671A1 (en) * | 1988-03-18 | 1989-09-28 | Schering Ag | PORPHYRINE COMPLEX COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM |
JPH0796558B2 (en) | 1988-03-31 | 1995-10-18 | 協和醗酵工業株式会社 | Modified polypeptide |
AU5858690A (en) | 1989-06-14 | 1991-01-08 | Cetus Corporation | Polymer/antibiotic conjugate |
DE4017439C2 (en) * | 1990-05-30 | 1994-06-23 | Deutsches Krebsforsch | Polyether-substituted tumor agents |
-
1991
- 1991-05-29 JP JP3509529A patent/JP2640293B2/en not_active Expired - Fee Related
- 1991-05-29 AT AT91910296T patent/ATE115864T1/en not_active IP Right Cessation
- 1991-05-29 WO PCT/EP1991/000992 patent/WO1991018630A1/en active IP Right Grant
- 1991-05-29 DE DE59103985T patent/DE59103985D1/en not_active Expired - Fee Related
- 1991-05-29 ES ES91910296T patent/ES2068587T3/en not_active Expired - Lifetime
- 1991-05-29 EP EP91910296A patent/EP0485563B1/en not_active Expired - Lifetime
- 1991-05-29 DK DK91910296.2T patent/DK0485563T3/en active
- 1991-12-02 DE DE4139715A patent/DE4139715C2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE4139715C2 (en) | 1994-08-11 |
ATE115864T1 (en) | 1995-01-15 |
EP0485563A1 (en) | 1992-05-20 |
JPH05501885A (en) | 1993-04-08 |
JP2640293B2 (en) | 1997-08-13 |
ES2068587T3 (en) | 1995-04-16 |
WO1991018630A1 (en) | 1991-12-12 |
DE59103985D1 (en) | 1995-02-02 |
EP0485563B1 (en) | 1994-12-21 |
DE4139715A1 (en) | 1993-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0485563T3 (en) | Polyether-substituted anti-tumor agents | |
ES507033A0 (en) | METHOD AND APPARATUS TO EXTRACT NARROW LINEAR ETHYLENE POLYMERS DISTRIBUTION OF MOLECULAR WEIGHT. | |
UY23635A1 (en) | PROCEDURE FOR THE PREPARATION OF PEG INTERFERON CONJUGATES | |
IT8026950A0 (en) | PARTICLES OF SUBSTANCES SOLUBLE IN LIPOIDS AND BIOLOGICALLY ACTIVE COMPOSITIONS THAT CONTAIN THEM. | |
DE3885317D1 (en) | Macromolecular platinum antitumor compounds. | |
NO166943C (en) | ANALOGY PROCEDURE FOR PREPARING ENZYMESRESISTENT IMMUNO MODULATING PEPTIDES. | |
AR001267A1 (en) | Carbon black treated method to prepare it polymeric formulation that includes device and shield that comprise said polymeric formulation | |
SE7611420L (en) | HIGH MOLECULAR POLYAMINES AND KITS FOR THEIR PREPARATION | |
FI942558A0 (en) | Melt-stable lactide polymer composition and process for its preparation | |
BR8406642A (en) | BISMALEIMIDE, "PREPRETABLE" RESIN COMPOSITION, PREPREG AND COMPOUND | |
SE7708687L (en) | COMPOSITION WITH HIGHLY SOLID SUBSTANCES | |
SE7612432L (en) | COMPOSITION AND PROCEDURE FOR DISPERGING HIGH MOLECULAR FLOCKING POLYMERS IN WATER | |
AR222763A1 (en) | COMPOSITIONS OF POLYMERS FOR THE TREATMENT OF DEPILED LEATHERS AND TANKED LEATHERS | |
FI870616A (en) | Polymer compositions which are used as light-degradable and heat-stabilized films | |
MX9306960A (en) | OAK BARK EXTRACT COMPOSITIONS, RELATED SYNTHETIC COMPOSITIONS, AND METHOD FOR USE. | |
ATE232394T1 (en) | USE OF MODIFIED C-REACTIVE PROTEIN TO PRODUCE A MEDICATION FOR THE TREATMENT OF CANCER | |
EP0215662A3 (en) | Anti-tumor protease preparations | |
FI940375A0 (en) | Peptides with organ protective effect, process for their preparation and their use in therapy | |
DK0610286T3 (en) | Recombinant immunotoxins | |
ES2052654T3 (en) | PREPARATION POLYMER HARDENABLE BY WATER. | |
SE7613855L (en) | PEPTIDKARBAZATER | |
FI913391A0 (en) | FOERFARANDE FOER DETEKTERING AV SMAOCELLCARCINOM OCH ANVAENDNING AV ACYLPEPTIDHYDROLAS OCH DENNA KODANDE SEKVENSER. | |
SE8000466L (en) | POLYMERIC IMMUNE REGULATED AGENTS | |
ES2088633T3 (en) | POLYSYLOXANIC STABILIZERS CONTAINING PHENOL GROUPS AND STERICALLY IMPAIRED OXAMIDIC GROUPS. | |
FI882278A (en) | Improved chromium catalyst compositions and polymerization process in which they are used |